Development of controlled release captopril granules coated with ethylcellulose and methylcellulose by fluid bed dryer

Drug Delivery

Volumn 15, Issue 1, 2008, Pages 11-18

  Stulzer, Hellen Karine ^a   Silva, Marcos Antonio Segatto ^a   Fernandes, Daniel ^a   Assreuy, Jamil ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Captopril; Controlled Release; Fluid Bed Dryer; Granules; Polymers

Indexed keywords

ANGIOTENSIN I; CAPTOPRIL; ETHYL CELLULOSE; METHYLCELLULOSE; POVIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG COATING; DRUG GRANULE; DRUG SOLUBILITY; FEMALE; FLUID FLOW; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPE; X RAY POWDER DIFFRACTION;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; FEMALE; HYPERTENSION; KINETICS; METHYLCELLULOSE; MICROSCOPY, ELECTRON, SCANNING; MODELS, CHEMICAL; POVIDONE; POWDER DIFFRACTION; POWDERS; RATS; RATS, WISTAR; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 38148998794     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540701827196     Document Type: Article

References (42)

1. Agnihotri, S. A., and Aminabhavi, T. M. 2004. Controlled release of clozapine through chitosan microparticles prepared by a novel method. J. Control Rel. 96:245-259.
2. Backer, R. W., and Lonsdale, H. K. 1993. Controlled release: mechanism and rates. In Controlled Release of Biological Active Agents ed. Tanquary, A. C., and Lacey, R. E. New York: Plenum Press.
3. Costa, P., and Lobo, J. M. 2001. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13:123-133.
4. Efentakis, M., and Vlachou, M. 2000. Evaluation of high molecular weight poly (oxyethylene) (Polyox) polymer: studies of flow properties and release rates of furosemide and captopril from controlled-release hard gelatin capsules. Pharm. Devel. Technol. 5:339-346.
5. rd ed. São Paulo, Brazil: Editora da Universidade de São Paulo.
6. Franklin, M. E., Addison, R. S., Baker, P. V., et al . 1998. Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography mass spectrometry and its application to pharmacokinetic studies. J. Chromatogr. 705:47-54.
7. Giron, D. 2003. Characterization of salts of drug substances. J. Therm. Anal. Calorim. 73:441-457.
8. Heng, P. W. S., Chan. L. W., and Tang, E. S. K. 2006. Use of swirling airflow to enhance coating performance of bottom spray fluid bed coaters. Int. J. Pharm. 327:26-35.
9. Higuchi, T. 1963. Mechanism of sustained-action medication: theoretical analysis of rate of release of solid dispersed in solid matrices. J. Pharm. Sc. 52:1145-1149.
10. Hixson, A. W., and Crowell, J. H. 1931. Dependence of reaction velocity upon surface and agitation.Ind. Eng. Chem. 23:923-931.
11. Ho, H. O., Wang, H .Y., and Sheu, M .T. 1997. The evaluation of granulated excipients as matrix material for controlled delivery of captopril. J. Control. Rel. 49:243-251.
12. Jinno, J., Kamada, N., Miyake, M., et al. 2006. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control Rel. 111:56-64.
13. Kaul, D., Nguyen, T. N., and Venkataram, S. 1992. Crystal habit modifications and altered tabletting characteristics. Int. J. Pharm. 88:345-350.
14. Khattab, I. S., Abdel-Rahman, S., Khidr, S., et al. 2001. Development and optimization of sustained-release captopril tablets and capsules. Egypt J. Biotechnol. 10:32-445.
15. Korsmeyer, R. W., Gurny, R., Doelker, E., et al. 1983. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 15:25-35.
16. Kristl, A., Srčič, S., Vrečer, F., et al. 1996. Polymorphism and pseudopolymorphism: influencing the dissolution properties of guanine derivative acyclovir. Int. J. Pharm. Sci. 139:231-235.
17. Langenbucher, F. 1972. Linearization of dissolution rate curves by the Weibull distribution. J. Pharm. Pharmacol. 24:979-981.
18. Markovich, R. J., Evans, C. A., Coscolluela, C. B., et al. 1997. Spectroscopic identification of an amorphous-to-crystalline drug transition in a solid dispersion SCH 48461 capsule formulation. J. Pharm. Biomed. Anal. 16:661-673.
19. Matharu, R. S., and Sanghavi, N. M. 1992. Novel drug delivery system for captopril. Drug Dev. Ind. Pharm. 18:1567-1574.
20. Munday, D. L., and Cox, P. L. 2000. Compressed xanthan and karaya gum matrices hydration, erosion and drug release mechanisms. Int. J. Pharm. 203:179-192.
21. Nixon, J. R. 1983. Release characterization of microcapsules. In:Biomedical Applications of Microcapsulation, ed. Lim, F. Boca Raton, FL: CRC Press.
22. Nur, A. O., and Zhang, J. S. 2000.Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Dev. Ind. Pharm. 26:965-969.
23. Pastrana, Y. C., Rivera, A. B., Enrique, T. E., et al. 2000. Caracterización farmacocinética de formulaciones orales de liberación sostenida. Factores que influyen en el perfil farmacocinético.Acta Farm. Bonaerense 19:25-34.
24. Petrillo, E. W., and Ondetti, M. A. 1982. Angiotensin-converting enzyme inhibitors: medicinal chemistry and biological actions. Med. Res. Rev. 2:1-41.
25. Purvis, T., Vaughn, J. M., Rogers, T. L., et al. 2006.Cryogenic liquids, nanoparticles, and microencapsulation. Int. J. Pharm. 324:43-50.
26. Ranga, R., Devi, K. D., and Buri, P. 1988. Cellulose matrices for zero-order release of soluble drugs. Drug Dev. Ind. Pharm. 14:2299-2320.
27. Regoli, D., Park, W. K., and Rioux, F. 1974. Pharmacology of angiotensin. Pharmacol Rev. 26:69-123.
28. Ribeiro, W., and Muscará, M. N. 2001. Características farmacocinéticas de antagonistas de cálcio, inibidores da ECA e antagonistas de angiotensina II em humanos. Rev Bras de Hipertens. 8:114-124.
29. Ritger, P. L., and Peppas, N. A. 1987a. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control Rel. 5:23-36.
30. Ritger, P. L., and Peppas, N. A. 1987b. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control Rel. 5:37-42.
31. Rhodes, C. T., and Porter, S. C. 1998. Coatings for controlled-release drug delivery systems. Drug Dev. Ind. Pharm. 24:1139-1154.
32. Romankiewicz, J. A., Brogden, R. N., Heel, R. C., et al. 1983. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs 25:6-40.
33. Royce, A. L. S., Weaver, M., and Shah, U. 2004. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2′-O-methyladenosine. J. Control. Rel. 97:79-90.
34. Saks, S. R., and Gardner, L. B. 1997. The pharmacoeconomic value of controlled-release dosage forms. J. Control Rel. 48:237-242.
35. Seta, Y., Higuchi, F., Kawahara, Y., et al. 1988. Design and preparation of captopril sustained release and dosage forms and their biopharmaceutical properties. Int. J. Pharm. 41:245-254.
36. Singh. J., and Robinson, D. H. 1988. Controlled release captopril microcapsules: effect of non-ionic surfactants on release from ethyl cellulose microcapsules. J. Microencapsul. 5:129-137.
37. Storpirts, S., Oliveira, P. G., Rodrigues, D., et al. 1999. Considerações biofarmacêuticas relevantes na fabricação de medicamentos genéricos: fatores que afetam a dissolução e a absorção de fármacos. Rev. Bras. Cien. Farm. 35:1-11.
38. Stulzer, H. K., and Silva, M. A. S. 2006. Estudo de estabilidade de grânulos revestidos e comprimidos contendo captopril. Acta Farm. Bonaerense 25:497-504.
39. Vudathala, G. K., and Rogers, J. A. 1995. Dissolution of fludrocortisone from biphasic polymers hydrogels. J. Control. Rel. 34:185-192.
40. Wagner, J. G. 1969. Interpretation of percentage dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J. Pharm. Sci. 58:1253-1257.
41. Wei, C., and Thau, M. 1996. Effect of particle size on the available surface area of nifedipine from nifedipine-polyethylene glycol 6000 solid dispersions. Int. J. Pharm. 127:261-272.
42. Wilding, I. R., Davis, S. S., Bakhshaee, M., et al. 1992. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharm. Res. 9:654-657.